ClinicalTrials.gg
CompletedNCT01092663Updated Jan 17, 2013Results posted

The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus

An interventional study of Colesevelam HCl and Sitagliptin in Diabetes Mellitus, Type 2, sponsored by KineMed. Completed at 3 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-01-17.

Sponsored by KineMed · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
123rd of 197
61 · median 102
Started
2010
with 22 others
No phase
22 of 198
none open now
Registered
86th of 198
by date

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 123rd largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2010, is one of 22 with no phase, and was the 86th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will assess the effects of colesevelam, alone or in combination with sitagliptin, on glucose metabolism in subjects with T2DM inadequately controlled by diet and exercise

Read the detailed description

The hypothesis is that co-administrationof colesevelam plus sitagliptin results in a greater reduction in HbA1c compared to colesevelam HCl treatment by

  1. improving the effects of colesevelam on fasting glucose metabolism
  2. improving the effects of colsevelam on postprandial glucose metabolism
03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Colesevelam
  • type 2 diabetes
  • sitagliptin
  • glucose metabolism
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female
  • Females of are on approved method
  • Negative pregnancy testing for females of childbearing potential
  • Previously diagnosed or newly diagnosed with T2DM drug naïve subjects
  • : 6.7-10%
  • Age 18 - 80 years
  • ≥ 18.5 kg/m2 and ≤ 40 kg/m2
  • Fasting serum glucose \< 300 mg/dL
  • Normal liver function, normal thyroid function, no history of liver, biliary or intestinal disease
  • Normal TSH
  • On stable diet and exercise routine for at least 4 weeks prior to screening
  • Has had a stable weight (+/-5%) for ≥3 months before screening

Exclusion criteria

Exclusion Criteria:

  • A history of type 1 diabetes mellitus or history of diabetic ketoacidosis
  • History of chronic (required daily for > 2 months) use of insulin therapy
  • Treatment with blood pressure lowering therapy that has not been stable for three months before screening
  • Treatment with lipid lowering medication other than statins
  • Treatment with statins that has not been stable for three months before screening
  • Treatment with a DPP-4 inhibitor or and GLP1 agonists at any time
  • Treatment with a thiazolidinedione (TZD) within the last 6 months of screening
  • History of an allergic or toxic reaction to sitagliptin or colesevelam
  • History of dysphagia, swallowing disorders, bowel obstruction, intestinal motility disorder, and gastrointestinal disorders
  • History of major gastrointestinal surgery
  • History of kidney problems
  • Fasting plasma triglycerides > 300 mg/dL
  • Serum LDL-C \<60 mg/dL
  • Positive toxicology test
  • Known to colesevelam HCl or sitagliptin.
  • Any to a study medication (colesevelam HCl or sitagliptin).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Active comparator
    Colesevelam HCl: 3 tablets, 2x/day

    Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.

    Drug: Colesevelam HCl

  • Active comparator
    Colesevelam plus Sitagliptin

    Colesevelam: Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks. Sitagliptin: Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.

    Drug: Colesevelam HCl · Drug: Sitagliptin

Interventions

  • Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.

    Also known as: Welchol

  • Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.

    Also known as: Januvia

06

What researchers measure

Primary outcomes

  1. Hemoglobin A1C

    Change from baseline in hemoglobin A1C after 12 weeks of colesevelam or colesevelam plus sitagliptin treatments

    Time frame: Baseline and 12 weeks

  2. Fasting Plasma Glucose

    Change from baseline in fasting plasma glucose concentrations after 12 weeks of colesevelam or colesevelam plus sitagliptin treatments.

    Time frame: Baseline and 12 weeks

  3. Fasting Endogenous Glucose Production

    Change from baseline in fasting endogenous glucose production after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatment

    Time frame: baseline and 12 weeks

  4. Fasting Gluconeogenesis

    Change from baseline in fasting gluconeogenesis after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatment

    Time frame: baseline and 12 weeks

  5. Fasting Glycogenolysis

    Change from baseline in fasting glycogenolysis after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatment

    Time frame: baseline and 12 weeks

  6. Fasting Plasma Glucose Clearance

    Change from baseline in fasting plasma glucose clearance after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments.

    Time frame: baseline and 12 weeks

  7. Appearance Rate of Oral Glucose

    Change from baseline in appearance rate of oral glucose after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments

    Time frame: baseline and 12 weeks

  8. Postprandial Endogenous Glucose Production

    Change from baseline in postprandial endogenous glucose production after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments Mean value was calculated using all results measured between 10 and 300 min post meal.

    Time frame: baseline and 12 weeks

  9. Postprandial Rate of Total Glucose Disposal Area Under the Curve (AUC)

    Change from baseline in postprandial rate of total glucose disposal (AUC) after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments AUC was calculated by the trapezoid method using all results measured between 0 and 300 min during the meal tolerance test.

    Time frame: baseline and 12 weeks

  10. Whole-body Glycolytic Disposal of Oral Glucose

    Change in baseline in whole-body glycolytic disposal of oral glucose after 12 weeks of colesevelam alone or colesevelam plus glucose treatments

    Time frame: baseline and 12 weeks

  11. Postprandial Glucose (AUC)

    Comparison between baseline and 12 weeks values of postrandial glucose (AUC).

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Fasting Plasma C-peptide

    To evaluate the effect of treatments on plamsa C-peptide concentrations.

    Time frame: Baseline and 12 weeks

  2. Fasting Plamsa Glucagon

    To evaluate the effect of treatments on plasma glucagon concentrations.

    Time frame: Baseline and 12 weeks

  3. Fasting Active Plasma Glucagon Like-Peptide 1 (GLP-1)

    To evaluate the effect of treatments on plasma GLP-1 concentrations.

    Time frame: Baseline and 12 weeks

  4. Fasting Plasma Total Glucose-dependent Insulinotropic Peptide (GIP)

    To evaluate the effect of treatments on plasma Glucose-dependent Insulinotropic Peptide (GIP) concentrations.

    Time frame: Baseline and 12 weeks

  5. Fasting Insulin

    To evaluate the effect of treatments on fasting insulin concentrations

    Time frame: Baseline and 12 weeks

  6. Postprandial Insulin (AUC)

    To evaluate the effect of treatments on postprandial insulin (AUC)

    Time frame: Baseline and 12 weeks

  7. Postprandial C-peptide (AUC)

    To evaluate the effect of treatments on postprandial C-peptide (AUC)

    Time frame: Baseline and 12 weeks

  8. Postprandial Active GLP-1 (AUC)

    To evaluate the effects of treatments on postprandial active GLP-1 (AUC)

    Time frame: Baseline and 12 weeks

  9. Postprandial Total GIP (AUC)

    To evaluate the effects of treatment on postprandial total GIP (AUC)

    Time frame: Baseline and 12 weeks

  10. Postprandial Glucagon (AUC)

    To evaluate the effects of treatment on postprandial glucagon (AUC)

    Time frame: Baseline and 12 weeks

07

Results

Posted Jan 17, 2013

Participant flow

Study period from February 2010 to December 2010. This was a multi-center, randomized, open-label, prospective, parallel-group study consisting of 12 weeks of active treatment.

Participant flow — Overall Study
MilestoneColesevelamColesevelam Plus Sitagliptin
Started3130
Completed2426
Not completed74
Withdrew: Withdrawal by subject32
Withdrew: Glucose >300mg/dl10
Withdrew: High fasting triglyceride20
Withdrew: Adverse event11
Withdrew: Protocol violation01

Outcome measures

PrimaryHemoglobin A1C

Change from baseline in hemoglobin A1C after 12 weeks of colesevelam or colesevelam plus sitagliptin treatments

Time frame:
Baseline and 12 weeks
Reported as:
Mean · percentage
Hemoglobin A1C
percentageColesevelamColesevelam Plus Sitagliptin
Hemoglobin A1C0.3 ± 1.2-0.1 ± 1.1
Statistical analysis
  • Colesevelam vs Colesevelam Plus Sitagliptin · t-test, 2 sided · p = >0.05unpaired t-test
SecondaryFasting Plasma C-peptide

To evaluate the effect of treatments on plamsa C-peptide concentrations.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · picomoles (pmol)/Liter (L)
Fasting Plasma C-peptide
picomoles (pmol)/Liter (L)ColesevelamColesevelam Plus Sitagliptin
Fasting Plasma C-peptide26 ± 217103 ± 195
Statistical analysis
  • Colesevelam vs Colesevelam Plus Sitagliptin · t-test, 2 sided · p = >0.05unpaired t-test
PrimaryFasting Plasma Glucose

Change from baseline in fasting plasma glucose concentrations after 12 weeks of colesevelam or colesevelam plus sitagliptin treatments.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · millimoles (mmol)/Liter (L)
Fasting Plasma Glucose
millimoles (mmol)/Liter (L)ColesevelamColesevelam Plus Sitagliptin
Fasting Plasma Glucose-0.8 ± 2.1-0.6 ± 2.3
Statistical analysis
  • Colesevelam vs Colesevelam Plus Sitagliptin · t-test, 2 sided · p = >0.05unpaired t-test
SecondaryFasting Plamsa Glucagon

To evaluate the effect of treatments on plasma glucagon concentrations.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · picograms (pg)/milliliter (ml)
Fasting Plamsa Glucagon
picograms (pg)/milliliter (ml)ColesevelamColesevelam Plus Sitagliptin
Fasting Plamsa Glucagon1 ± 220 ± 17
Statistical analysis
  • Colesevelam vs Colesevelam Plus Sitagliptin · t-test, 2 sided · p = >0.05unpaired t-test
SecondaryFasting Active Plasma Glucagon Like-Peptide 1 (GLP-1)

To evaluate the effect of treatments on plasma GLP-1 concentrations.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · pmol/L
Fasting Active Plasma Glucagon Like-Peptide 1 (GLP-1)
pmol/LColesevelamColesevelam Plus Sitagliptin
Fasting Active Plasma Glucagon Like-Peptide 1 (GLP-1)2.4 ± 4.22.8 ± 8.4
Statistical analysis
  • Colesevelam vs Colesevelam Plus Sitagliptin · t-test, 2 sided · p = >0.05unpaired t-test
SecondaryFasting Plasma Total Glucose-dependent Insulinotropic Peptide (GIP)

To evaluate the effect of treatments on plasma Glucose-dependent Insulinotropic Peptide (GIP) concentrations.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · pmol/L
Fasting Plasma Total Glucose-dependent Insulinotropic Peptide (GIP)
pmol/LColesevelamColesevelam Plus Sitagliptin
Fasting Plasma Total Glucose-dependent Insulinotropic Peptide (GIP)1.8 ± 8.5-1.3 ± 3.4
Statistical analysis
  • Colesevelam vs Colesevelam Plus Sitagliptin · t-test, 2 sided · p = <0.05unpaired t-test
PrimaryFasting Endogenous Glucose Production

Change from baseline in fasting endogenous glucose production after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatment

Time frame:
baseline and 12 weeks
Reported as:
Mean · micromoles (umol) per kg FFM per min
Fasting Endogenous Glucose Production
micromoles (umol) per kg FFM per minColesevelamColesevelam Plus Sitagliptin
Fasting Endogenous Glucose Production1.0 ± 4.41.0 ± 3.3
Statistical analysis
  • Colesevelam vs Colesevelam Plus Sitagliptin · t-test, 2 sided · p = >0.05unpaired t-test
PrimaryFasting Gluconeogenesis

Change from baseline in fasting gluconeogenesis after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatment

Time frame:
baseline and 12 weeks
Reported as:
Mean · umol per kilogram (kg) FFM per min
Fasting Gluconeogenesis
umol per kilogram (kg) FFM per minColesevelamColesevelam Plus Sitagliptin
Fasting Gluconeogenesis0.2 ± 1.5-0.3 ± 1.3
Statistical analysis
  • Colesevelam vs Colesevelam Plus Sitagliptin · t-test, 2 sided · p = >0.05unpaired t-test
PrimaryFasting Glycogenolysis

Change from baseline in fasting glycogenolysis after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatment

Time frame:
baseline and 12 weeks
Reported as:
Mean · umol per kg Fat-Free Mass (FFM) per min
Fasting Glycogenolysis
umol per kg Fat-Free Mass (FFM) per minColesevelamColesevelam Plus Sitagliptin
Fasting Glycogenolysis0.8 ± 3.61.7 ± 3.0
Statistical analysis
  • Colesevelam vs Colesevelam Plus Sitagliptin · t-test, 2 sided · p = >0.05unpaired ttest
PrimaryFasting Plasma Glucose Clearance

Change from baseline in fasting plasma glucose clearance after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments.

Time frame:
baseline and 12 weeks
Reported as:
Mean · ml per kg FFM per minute (min)
Fasting Plasma Glucose Clearance
ml per kg FFM per minute (min)ColesevelamColesevelam Plus Sitagliptin
Fasting Plasma Glucose Clearance0.30 ± 0.350.27 ± 0.41
Statistical analysis
  • Colesevelam vs Colesevelam Plus Sitagliptin · t-test, 2 sided · p = >0.05unpaired t-test
PrimaryAppearance Rate of Oral Glucose

Change from baseline in appearance rate of oral glucose after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments

Time frame:
baseline and 12 weeks
Reported as:
Mean · umol per kg per min
Appearance Rate of Oral Glucose
umol per kg per minColesevelamColesevelam Plus Sitagliptin
Appearance Rate of Oral Glucose118 ± 613-244 ± 464
Statistical analysis
  • Colesevelam vs Colesevelam Plus Sitagliptin · t-test, 2 sided · p = =0.01unpaired t-test
PrimaryPostprandial Endogenous Glucose Production

Change from baseline in postprandial endogenous glucose production after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments Mean value was calculated using all results measured between 10 and 300 min post meal.

Time frame:
baseline and 12 weeks
Reported as:
Mean · umol per kg per min
Postprandial Endogenous Glucose Production
umol per kg per minColesevelamColesevelam Plus Sitagliptin
Postprandial Endogenous Glucose Production-0.1 ± 2.0-0.2 ± 1.5
Statistical analysis
  • Colesevelam vs Colesevelam Plus Sitagliptin · t-test, 2 sided · p = >0.05unpaired t-test
PrimaryPostprandial Rate of Total Glucose Disposal Area Under the Curve (AUC)

Change from baseline in postprandial rate of total glucose disposal (AUC) after 12 weeks of colesevelam alone or colesevelam plus sitagliptin treatments AUC was calculated by the trapezoid method using all results measured between 0 and 300 min during the meal tolerance test.

Time frame:
baseline and 12 weeks
Reported as:
Mean · umol per kg per min
Postprandial Rate of Total Glucose Disposal Area Under the Curve (AUC)
umol per kg per minColesevelamColesevelam Plus Sitagliptin
Postprandial Rate of Total Glucose Disposal Area Under the Curve (AUC)-10 ± 914-256 ± 627
Statistical analysis
  • Colesevelam vs Colesevelam Plus Sitagliptin · t-test, 2 sided · p = >0.05unpaired t-test
PrimaryWhole-body Glycolytic Disposal of Oral Glucose

Change in baseline in whole-body glycolytic disposal of oral glucose after 12 weeks of colesevelam alone or colesevelam plus glucose treatments

Time frame:
baseline and 12 weeks
Reported as:
Mean · Percent of Load
Whole-body Glycolytic Disposal of Oral Glucose
Percent of LoadColesevelamColesevelam Plus Sitagliptin
Whole-body Glycolytic Disposal of Oral Glucose4 ± 62 ± 6
Statistical analysis
  • Colesevelam vs Colesevelam Plus Sitagliptin · t-test, 2 sided · p = >0.05unpaired t-test
PrimaryPostprandial Glucose (AUC)

Comparison between baseline and 12 weeks values of postrandial glucose (AUC).

Time frame:
Baseline and 12 weeks
Reported as:
Mean · millimoles (mmol)/l x min
Postprandial Glucose (AUC)
millimoles (mmol)/l x minColesevelamColesevelam Plus Sitagliptin
Postprandial Glucose (AUC)-1.1 ± 2.6-1.5 ± 2.8
Statistical analysis
  • Colesevelam vs Colesevelam Plus Sitagliptin · t-test, 2 sided · p = >0.05unpaired t-test
SecondaryFasting Insulin

To evaluate the effect of treatments on fasting insulin concentrations

Time frame:
Baseline and 12 weeks
Reported as:
Mean · pmol/L
Fasting Insulin
pmol/LColesevelamColesevelam Plus Sitagliptin
Fasting Insulin6 ± 3812 ± 36
Statistical analysis
  • Colesevelam vs Colesevelam Plus Sitagliptin · t-test, 2 sided · p = >0.05unpaired t-test
SecondaryPostprandial Insulin (AUC)

To evaluate the effect of treatments on postprandial insulin (AUC)

Time frame:
Baseline and 12 weeks
Reported as:
Mean · pmol/l x min
Postprandial Insulin (AUC)
pmol/l x minColesevelamColesevelam Plus Sitagliptin
Postprandial Insulin (AUC)-13 ± 11840 ± 73
Statistical analysis
  • Colesevelam vs Colesevelam Plus Sitagliptin · t-test, 2 sided · p = <0.05unpaired t-test
SecondaryPostprandial C-peptide (AUC)

To evaluate the effect of treatments on postprandial C-peptide (AUC)

Time frame:
Baseline and 12 weeks
Reported as:
Mean · pmol/l x min
Postprandial C-peptide (AUC)
pmol/l x minColesevelamColesevelam Plus Sitagliptin
Postprandial C-peptide (AUC)30 ± 390193 ± 367
Statistical analysis
  • Colesevelam vs Colesevelam Plus Sitagliptin · t-test, 2 sided · p = <0.05unpaired t-test
SecondaryPostprandial Active GLP-1 (AUC)

To evaluate the effects of treatments on postprandial active GLP-1 (AUC)

Time frame:
Baseline and 12 weeks
Reported as:
Mean · pmol/l x min
Postprandial Active GLP-1 (AUC)
pmol/l x minColesevelamColesevelam Plus Sitagliptin
Postprandial Active GLP-1 (AUC)1.8 ± 7.96.6 ± 4.9
Statistical analysis
  • Colesevelam vs Colesevelam Plus Sitagliptin · t-test, 2 sided · p = <0.01unpaired t-test
SecondaryPostprandial Total GIP (AUC)

To evaluate the effects of treatment on postprandial total GIP (AUC)

Time frame:
Baseline and 12 weeks
Reported as:
Mean · pmol/l x min
Postprandial Total GIP (AUC)
pmol/l x minColesevelamColesevelam Plus Sitagliptin
Postprandial Total GIP (AUC)-2 ± 6-5 ± 7
Statistical analysis
  • Colesevelam vs Colesevelam Plus Sitagliptin · t-test, 2 sided · p = <0.01unpaired t-test
SecondaryPostprandial Glucagon (AUC)

To evaluate the effects of treatment on postprandial glucagon (AUC)

Time frame:
Baseline and 12 weeks
Reported as:
Mean · picograms (pg)/milliter (ml) x min
Postprandial Glucagon (AUC)
picograms (pg)/milliter (ml) x minColesevelamColesevelam Plus Sitagliptin
Postprandial Glucagon (AUC)-7 ± 15-4.7 ± 11
Statistical analysis
  • Colesevelam vs Colesevelam Plus Sitagliptin · t-test, 2 sided · p = >0.05unpaired t-test

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Colesevelam—0/31 (0%)1/31 (3.2%)
Colesevelam Plus Sitagliptin—0/30 (0%)1/30 (3.3%)
Most frequent other events
Most frequent other events
EventColesevelamColesevelam Plus Sitagliptin
Non-related Adverse EventGeneral disorders0/311/30
Tingling sensation in lower extremitiesNervous system disorders1/310/30

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ColesevelamColesevelam Plus SitagliptinTotal
<=18 years000
Between 18 and 65 years242145
>=65 years7916
Age Continuous
Age Continuous(years)ColesevelamColesevelam Plus SitagliptinTotal
Mean56 ± 955 ± 1355.5 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)ColesevelamColesevelam Plus SitagliptinTotal
Female121426
Male191635
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ColesevelamColesevelam Plus SitagliptinTotal
Hispanic or Latino302959
Not Hispanic or Latino112
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ColesevelamColesevelam Plus SitagliptinTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American527
White262753
More than one race000
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(participants)ColesevelamColesevelam Plus SitagliptinTotal
United States313061
Weight
Weight(kilograms)ColesevelamColesevelam Plus SitagliptinTotal
Mean84.6 ± 15.385.1 ± 17.084.85 ± 16.15
BMI
BMI(kilograms/square meter (kg/m2))ColesevelamColesevelam Plus SitagliptinTotal
Mean30.7 ± 3.730.9 ± 4.730.8 ± 4.2

10 further baseline measures are reported on the registry.

08

Study locations

3 sites
  • University of California, San Francisco
    San Francisco, California 94110, United States
  • Clinical Pharmacology of Miami
    Miami, Florida 33014, United States
  • Healthcare Discoveries, LLC d/b/a ICON Development Solutions
    San Antonio, Texas 78209, United States
09

References and documents

Publications

  • Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther. 2007 Jan;29(1):74-83. doi: 10.1016/j.clinthera.2007.01.003. PubMed 17379048 ↗
  • Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med. 2008 Oct 13;168(18):1975-83. doi: 10.1001/archinte.168.18.1975. PubMed 18852398 ↗
  • Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008 Aug;31(8):1479-84. doi: 10.2337/dc08-0283. Epub 2008 May 5. PubMed 18458145 ↗
  • Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med. 2008 Jul 28;168(14):1531-40. doi: 10.1001/archinte.168.14.1531. PubMed 18663165 ↗
  • Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006 Dec;29(12):2632-7. doi: 10.2337/dc06-0703. PubMed 17130196 ↗
  • Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007 Mar;9(2):194-205. doi: 10.1111/j.1463-1326.2006.00704.x. PubMed 17300595 ↗
  • Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007 Aug;30(8):1979-87. doi: 10.2337/dc07-0627. Epub 2007 May 7. Erratum In: Diabetes Care. 2008 Aug;31(8):1713. PubMed 17485570 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2010
First posted
Mar 25, 2010
Start
Mar 2010
Primary completionActual
Jul 2011
CompletionActual
Jul 2011
Results first posted
Jan 17, 2013
Last update
Jan 17, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01092663
Lead sponsor
KineMed
Responsible party
Sponsor
First posted
Mar 25, 2010
Start date
Mar 2010
Primary completion
Jul 2011
Completion
Jul 2011
Results posted
Jan 17, 2013
Last update
Jan 17, 2013

Study contacts

Carine Beysen, DPhil
principal investigator · KineMed, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion